{
    "nctId": "NCT01948960",
    "briefTitle": "Influence of Exceptional Patient Characteristics on Everolimus Exposure",
    "officialTitle": "Influence of Exceptional Patient Characteristics on Everolimus Exposure",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 56,
    "primaryOutcomeMeasure": "everolimus AUC",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult women (\u2265 18 years of age) with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.\n* Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer\n* Postmenopausal women\n* Radiological or clinical evidence of recurrence or progression on last systemic therapy prior to enrollment.\n* Progression following a non-steroidal aromatase inhibitor\n* Falling into one of the following categories\n\n  * elderly patients (age \u2265 70 years and BMI \\< 30 kg/m2); or\n  * obese patients (BMI \u2265 30 kg/m2 and age \\< 70 years); or\n  * control patients (BMI \\< 30 kg/m2 and age \\< 70 years);\n* Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 5 x ULN\n* Adequate renal function: calculated creatinine clearance, as estimated by GFR using the MDRD formula, is \u2265 30ml/min/1.73m2\n* Performance status ECOG 0 - 2 (Karnofsky index: 60 - 100)\n* Patient is willing and able to sign the Informed Consent Form prior to screening evaluations\n\nExclusion Criteria:\n\n* Patients aged \u2265 70 years AND BMI \u2265 30 kg/m2\n* HER2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).\n* Previous treatment with exemestane or mTOR inhibitors. Except for the treatment with exemestane in the adjuvant setting.\n* Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin).\n* Patients with a known history of HIV seropositivity.\n* Any severe and / or uncontrolled medical conditions such as:\n\n  * Unstable angina pectoris, serious uncontrolled cardiac arrhythmia\n  * Patients with severe hepatic impairment (Child-Pugh A/B/C)\n  * Uncontrolled diabetes mellitus\n  * Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)\n* Patients who test positive for hepatitis B or C\n* Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A within the last 5 days prior to enrollment\n* History of non-compliance to medical regimens\n* Patients unwilling to or unable to comply with the protocol",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}